GO:0042371 vitamin K biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042371 vitamin K biosynthetic process describes the chemical reactions and pathways that form any form of vitamin K, quinone-derived vitamins involved in blood-clotting factor synthesis in mammals.
• Vitamin K exists mainly as phylloquinone (vitamin K1) from plants and menaquinones (vitamin K2) from bacteria, with distinct biosynthetic routes and tissue distributions.
• The classical mammalian vitamin K cycle recycles vitamin K hydroquinone to support gamma-glutamyl carboxylation of clotting factors and other vitamin K-dependent proteins.
• Bacterial menaquinone biosynthesis proceeds through the menaquinone (men) pathway, while plant phylloquinone biosynthesis occurs in chloroplasts via the phylloquinone (phyllo) pathway.
• Disruption of vitamin K biosynthesis or recycling causes bleeding disorders, and vitamin K status has been linked to bone and vascular health.
• CRISPR knockout, knock-in, point-mutation and overexpression models enable causal dissection of vitamin K biosynthetic genes in microbes, plants and mammalian cells.
Description
GO:0042371 vitamin K biosynthetic process is the biological process ontology term for the chemical reactions and pathways that result in the formation of any form of vitamin K, a group of quinone-derived vitamins required for the synthesis of blood-clotting factors in mammals. Vitamin K is not a single molecule but a family of naphthoquinones, principally phylloquinone (vitamin K1) produced by plants and menaquinones (vitamin K2) produced by bacteria, which differ in their isoprenoid side chains and biological half-lives. Because these vitamins are essential for post-translational gamma-carboxylation of vitamin K-dependent proteins, the biosynthetic process is central to hemostasis and to broader physiological roles that continue to be clarified. For researchers, GO:0042371 provides a controlled vocabulary to annotate genes and pathways across species, from bacterial menaquinone biosynthesis to plant chloroplast phylloquinone production and mammalian vitamin K recycling. The term is used in functional genomics, microbial engineering and plant biotechnology, where the goal is often to increase vitamin K yield or to understand how its availability affects downstream carboxylation reactions. In mammals, the biosynthetic and recycling steps are tightly coupled to the vitamin K cycle, which regenerates the hydroquinone form needed by gamma-glutamyl carboxylase. This article summarizes the authoritative QuickGO definition, the major stages of the process, the genes and enzymes involved, and the experimental models, including CRISPR-based approaches, that are used to study vitamin K biosynthesis and its links to human disease.
vitamin K biosynthetic process At A Glance
| GO ID | GO:0042371 |
|---|---|
| GO term | vitamin K biosynthetic process |
| Ontology | biological_process |
| Synonym | naphthoquinone metabolic process; naphthoquinone metabolism; vitamin K anabolism; vitamin K biosynthesis; vitamin K formation; vitamin K synthesis |
| Major function | Formation of quinone-derived vitamin K vitamins (phylloquinone, menaquinones) that support blood-clotting factor synthesis in mammals |
| Definition source | QuickGO definition: chemical reactions and pathways resulting in the formation of any of the forms of vitamin K |
| Related process | Vitamin K cycle and gamma-glutamyl carboxylation of vitamin K-dependent proteins |
| Taxonomic scope | Bacteria, plants and other organisms that synthesize vitamin K; mammals rely on dietary intake and recycling |
| Representative pathways | Bacterial menaquinone biosynthesis; plant phylloquinone biosynthesis in chloroplasts |
What Is GO:0042371?
According to the QuickGO definition, GO:0042371 vitamin K biosynthetic process encompasses the chemical reactions and pathways resulting in the formation of any of the forms of vitamin K, which are quinone-derived vitamins involved in the synthesis of blood-clotting factors in mammals. In other words, it is the biosynthetic half of vitamin K metabolism: the enzymatic steps that build phylloquinone, menaquinone or related naphthoquinone vitamins from simpler precursors, rather than the later recycling or utilization reactions.
Why Is vitamin K biosynthetic process Important in Cell Biology?
Vitamin K biosynthesis matters because it supplies the quinone cofactor that drives gamma-glutamyl carboxylation, a post-translational modification essential for the activity of blood-clotting factors such as prothrombin and factors VII, IX and X. Without a functional biosynthetic or recycling route, vitamin K-dependent carboxylation fails, leading to bleeding tendency and, in newborns, vitamin K deficiency bleeding. Beyond coagulation, vitamin K status has been associated with bone and vascular health, and the distinction between vitamin K1 and K2 forms has implications for bioavailability and tissue distribution. Understanding GO:0042371 therefore supports both fundamental enzymology and applied work in microbial and plant production of vitamin K.
• Provides the quinone cofactor required for gamma-glutamyl carboxylation of clotting factors.
• Deficiency or impaired recycling causes bleeding disorders, including vitamin K deficiency bleeding in infants.
• Vitamin K1 and K2 forms differ in side chain, source and biological behavior, affecting nutrition and therapeutics.
• Bacterial menaquinone biosynthesis is a target for antimicrobial and metabolic engineering research.
• Plant phylloquinone biosynthesis in chloroplasts is central to photosynthetic organism biology and crop quality.
• Vitamin K status has been linked to bone and vascular health beyond coagulation.
• The vitamin K cycle connects biosynthesis, recycling and utilization, making it a model for coupled redox pathways.
• CRISPR models allow causal testing of biosynthetic genes in microbes, plants and mammalian cells.
• GO:0042371 supports cross-species annotation and comparative genomics of quinone biosynthesis.
• Biotechnological production of vitamin K1 is an emerging sustainable route to this essential nutrient.
What Happens During vitamin K biosynthetic process?
Overview of vitamin K forms and biosynthetic routes
In simple terms: Vitamin K is not one molecule but a family, and different organisms build different family members.
Vitamin K comprises phylloquinone (vitamin K1), synthesized by plants, and menaquinones (vitamin K2), synthesized by bacteria and other organisms; these forms share a naphthoquinone ring but differ in their isoprenoid side chains. The biosynthetic process therefore branches according to organism: the bacterial menaquinone pathway and the plant phylloquinone pathway are the best-characterized routes. In mammals, vitamin K is obtained from diet and recycled rather than synthesized de novo, but the same quinone chemistry underlies its function.
Bacterial menaquinone biosynthesis
In simple terms: Bacteria build menaquinone through a dedicated set of enzymes known as the men pathway.
In bacteria, menaquinone biosynthesis proceeds through the menaquinone (men) pathway, in which a series of enzymes convert chorismate and related precursors into the naphthoquinone ring and attach a prenylated side chain. This pathway is important both for bacterial respiration and as a source of vitamin K2 in the human diet and microbiome. Because menaquinone is essential for some pathogens, the pathway has attracted interest as a target for antimicrobial development.
Plant phylloquinone biosynthesis in chloroplasts
In simple terms: Plants make vitamin K1 inside chloroplasts as part of their photosynthetic machinery.
In photosynthetic organisms, phylloquinone biosynthesis occurs in chloroplasts and is closely tied to the synthesis of photosynthetic electron carriers. Phylloquinone serves as a key electron acceptor in photosystem I, linking vitamin K biosynthesis to photosynthesis and to the broader metabolism of photosynthetic organisms. The plant pathway is also the main dietary source of vitamin K1 for humans and animals.
The vitamin K cycle and gamma-carboxylation
In simple terms: Once vitamin K is available, cells recycle it to power a reaction that activates clotting proteins.
The vitamin K cycle couples the reduced hydroquinone form of vitamin K to gamma-glutamyl carboxylase, which carboxylates glutamate residues in vitamin K-dependent proteins such as clotting factors. During this reaction, vitamin K hydroquinone is oxidized to vitamin K epoxide, which is then reduced back to the quinone and hydroquinone forms by vitamin K epoxide reductase and related enzymes. This recycling ensures that limited vitamin K can support repeated carboxylation cycles, and it is the point at which anticoagulants such as warfarin act.
Regulation and integration with cellular metabolism
In simple terms: Vitamin K biosynthesis is tuned to the needs of the organism and its environment.
Biosynthetic flux is influenced by precursor availability, enzyme expression and, in photosynthetic organisms, by chloroplast development and light. In bacteria, menaquinone levels respond to respiratory and metabolic demands, while in mammals the effective pool of vitamin K depends on dietary intake and recycling efficiency. These regulatory layers connect GO:0042371 to respiration, photosynthesis and hemostasis.
Key Genes Involved in GO:0042371 vitamin K biosynthetic process
The following genes and enzymes are representative of the vitamin K biosynthetic process and its associated cycle across bacteria, plants and mammals.
| Gene | Major Role | Research Relevance |
|---|---|---|
| menA | Bacterial menaquinone biosynthesis enzyme | Target for menaquinone pathway studies and antimicrobial research |
| menB | Bacterial menaquinone biosynthesis enzyme | Model for dissecting men pathway steps |
| menC | Bacterial menaquinone biosynthesis enzyme | Functional genomics of menaquinone production |
| menD | Bacterial menaquinone biosynthesis enzyme | Enzyme mechanism and pathway engineering |
| menE | Bacterial menaquinone biosynthesis enzyme | Candidate for metabolic engineering of vitamin K2 |
| menF | Bacterial menaquinone biosynthesis enzyme | Comparative genomics of quinone biosynthesis |
| menH | Bacterial menaquinone biosynthesis enzyme | Pathway annotation and knockout studies |
| menI | Bacterial menaquinone biosynthesis enzyme | Enzyme structure-function research |
| GGCX | Gamma-glutamyl carboxylase, uses vitamin K hydroquinone | Central to vitamin K-dependent clotting factor activation |
| VKORC1 | Vitamin K epoxide reductase, recycles vitamin K | Target of warfarin and key to the vitamin K cycle |
| VKORC1L1 | Vitamin K epoxide reductase-like protein | Vitamin K recycling and redox biology |
| F9 | Vitamin K-dependent clotting factor IX | Model for carboxylation-dependent secretion and activity |
| F10 | Vitamin K-dependent clotting factor X | Readout of vitamin K status and carboxylation |
| F7 | Vitamin K-dependent clotting factor VII | Clinical marker of vitamin K function |
| PROC | Vitamin K-dependent protein C | Anticoagulant pathway linked to vitamin K |
| PROS1 | Vitamin K-dependent protein S | Anticoagulant pathway linked to vitamin K |
| MGP | Matrix Gla protein, vitamin K-dependent | Vascular calcification and vitamin K biology |
| BGLAP | Osteocalcin, vitamin K-dependent | Bone health and vitamin K status |
How Is vitamin K biosynthetic process Regulated?
Vitamin K biosynthesis and the effective vitamin K pool are regulated at multiple levels. In bacteria, menaquinone pathway gene expression responds to respiratory and metabolic conditions, while in photosynthetic organisms phylloquinone production is tied to chloroplast development and photosynthetic demand. In mammals, vitamin K availability is governed by dietary intake and by the vitamin K cycle, in which VKORC1 and related reductases regenerate the hydroquinone form required by GGCX. This recycling loop is the pharmacological target of vitamin K antagonists such as warfarin, which reduce regeneration of reduced vitamin K and thereby limit gamma-carboxylation of clotting factors. Vitamin K status also interacts with broader nutritional and metabolic factors, as reflected in ongoing discussion of vitamin K conundrums in human health.
vitamin K biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GGCX | Vitamin K-dependent carboxylation deficiency and bleeding | Knockout or point-mutation cell models with clotting factor readouts |
| VKORC1 | Warfarin sensitivity and vitamin K cycle defects | Knock-in of variant alleles and dose-response studies |
| MGP | Vascular calcification linked to vitamin K status | Overexpression and knockout models in vascular cells |
| BGLAP | Bone health and osteocalcin carboxylation | Point-mutation knock-in for carboxylation sites |
| men pathway genes | Bacterial menaquinone production and respiration | Knockout and complementation in bacterial strains |
Bleeding disorders and vitamin K deficiency
Impaired vitamin K availability or recycling reduces gamma-carboxylation of clotting factors, leading to bleeding tendency; this is most dramatic in vitamin K deficiency bleeding of newborns and in patients on vitamin K antagonist therapy. The vitamin K cycle is the mechanistic link between biosynthesis, recycling and coagulation, and its disruption is a direct cause of coagulopathy.
Bone and vascular health
Vitamin K-dependent proteins such as osteocalcin and matrix Gla protein are involved in bone mineralization and vascular calcification, and vitamin K status has been associated with these processes. The distinction between vitamin K1 and K2 forms may influence bioavailability and tissue effects, which is an active area of research.
Microbial and plant biotechnology
Because bacteria and plants synthesize vitamin K through dedicated pathways, these organisms are used for biotechnological production of vitamin K1 and K2. Understanding the biosynthetic enzymes supports metabolic engineering and sustainable production of this essential nutrient.
From vitamin K biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for vitamin K biosynthesis? | CRISPR knockout in bacterial or plant cells followed by metabolite measurement |
| Does a specific enzyme residue control substrate specificity? | Point-mutation knock-in of the catalytic residue |
| Can a tagged enzyme be used to track pathway localization? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression increase vitamin K yield? | Overexpression of biosynthetic genes in microbial or plant hosts |
| Which genes are essential for vitamin K-dependent carboxylation? | Knockout of GGCX or VKORC1 with clotting factor readouts |
| How does a disease variant affect vitamin K recycling? | Knock-in of patient variants in VKORC1 or related genes |
How to Study the vitamin K biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Phylloquinone and menaquinone concentrations | Quantifying vitamin K production in cells or engineered strains |
| RNA-seq | Expression of biosynthetic and cycle genes | Identifying condition-dependent regulation |
| CRISPR knockout | Requirement of a gene for vitamin K biosynthesis | Functional validation of candidate genes |
| Point-mutation knock-in | Effect of a specific residue on enzyme activity | Mechanistic enzymology of biosynthetic enzymes |
| Gamma-carboxylation assay | Activity of vitamin K-dependent carboxylation | Assessing GGCX function and vitamin K availability |
| VKOR activity assay | Vitamin K epoxide reduction | Studying the vitamin K cycle and warfarin response |
| Fluorescent tagging | Subcellular localization of pathway enzymes | Tracking chloroplast or bacterial membrane proteins |
| Comparative genomics | Conservation of biosynthetic gene clusters | Annotating men and phyllo pathways across species |
Metabolite profiling and mass spectrometry
Measuring phylloquinone and menaquinone levels by mass spectrometry is the most direct way to assess vitamin K biosynthetic flux in cells and tissues. These methods are used to compare wild-type and mutant strains or to quantify production in engineered organisms.
Transcriptomics and functional genomics
RNA-seq and comparative genomics help identify biosynthetic gene clusters and expression changes in response to conditions that alter vitamin K production. In photosynthetic organisms, transcript profiling can link phylloquinone biosynthesis to chloroplast development.
Enzymology and carboxylation assays
In vitro assays of gamma-glutamyl carboxylase and vitamin K epoxide reductase measure the activity of the vitamin K cycle and the impact of mutations. These assays are central to understanding how biosynthetic and recycling steps are coupled.
CRISPR screens and targeted editing
Pooled CRISPR screens can identify genes that influence vitamin K levels or vitamin K-dependent phenotypes, while targeted editing validates hits. Such approaches are increasingly used in microbial and mammalian systems to dissect the pathway.
How CRISPR Can Be Used to Study GO:0042371 vitamin K biosynthetic process
Knockout
CRISPR knockout of candidate biosynthetic genes in bacteria, plants or mammalian cells can establish whether a gene is required for vitamin K production or for vitamin K-dependent carboxylation. Knockout of GGCX or VKORC1 provides a clean background to study the vitamin K cycle and its role in clotting factor activation.
Point Mutation
Point-mutation knock-in allows precise testing of catalytic residues or regulatory sites in vitamin K biosynthetic enzymes, revealing structure-function relationships that cannot be inferred from deletion alone. Such models are useful for studying warfarin resistance variants in VKORC1.
Knock-in
Knock-in of tags or reporter sequences into endogenous biosynthetic genes enables tracking of enzyme localization and expression without overexpression artifacts. This is particularly valuable for chloroplast-targeted phylloquinone enzymes.
Overexpression
Overexpression of biosynthetic genes is a common strategy to increase vitamin K yield in microbial or plant systems and to test whether a step is rate-limiting. Overexpression of vitamin K cycle components can also amplify carboxylation readouts in cell models.
How EDITGENE Supports vitamin K biosynthetic process Research
Researchers studying vitamin K biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in vitamin K production, recycling or downstream carboxylation. EDITGENE provides CRISPR-based cell models and screening services that let you move from correlation to causation with validated edits and quantitative readouts.
Contact EDITGENE today to design your custom CRISPR model for vitamin K biosynthetic process research.
Frequently Asked Questions About vitamin K biosynthetic process
What is GO:0042371 vitamin K biosynthetic process?
It is the biological process ontology term for the chemical reactions and pathways that form any form of vitamin K, quinone-derived vitamins involved in blood-clotting factor synthesis in mammals.
What genes are involved in vitamin K biosynthetic process?
Representative genes include bacterial men pathway genes such as menA and menB, plant phylloquinone biosynthetic genes, and mammalian cycle genes such as GGCX and VKORC1.
What is the difference between vitamin K1 and vitamin K2?
Vitamin K1 (phylloquinone) is produced by plants, while vitamin K2 (menaquinones) are produced by bacteria; they differ in side chain structure and biological behavior.
Why is vitamin K important for blood clotting?
Vitamin K hydroquinone is required by gamma-glutamyl carboxylase to activate clotting factors, and the vitamin K cycle regenerates the reduced form.
Do humans synthesize vitamin K?
Mammals do not synthesize vitamin K de novo; they obtain it from diet and recycle it through the vitamin K cycle.
How is vitamin K biosynthesis studied?
Researchers use metabolite profiling, RNA-seq, enzymology and CRISPR editing to measure vitamin K levels and test gene function.
What diseases are linked to vitamin K biosynthesis and metabolism?
Impaired vitamin K status or recycling causes bleeding disorders, and vitamin K has been linked to bone and vascular health.
Can CRISPR be used to study vitamin K biosynthetic genes?
Yes, CRISPR knockout, knock-in, point mutation and overexpression models are widely used to dissect biosynthetic and cycle genes.
What is the vitamin K cycle?
It is the recycling pathway that converts vitamin K epoxide back to the hydroquinone form needed for gamma-carboxylation, involving VKORC1 and related enzymes.
Which organisms are used to produce vitamin K biotechnologically?
Bacteria and plants are used, with bacterial menaquinone pathways and plant phylloquinone biosynthesis as key routes.
Conclusion
GO:0042371 vitamin K biosynthetic process captures the enzymatic routes that produce phylloquinone and menaquinones, the quinone vitamins that support blood-clotting factor synthesis and other vitamin K-dependent functions. Its study spans bacterial menaquinone pathways, plant chloroplast phylloquinone biosynthesis and the mammalian vitamin K cycle, with direct relevance to bleeding disorders, bone and vascular health, and biotechnological production. CRISPR-based models now make it possible to test the causal role of each gene and variant in this pathway, accelerating both mechanistic and translational research.
References
- 1. Traber MG. 2014. Vitamin K conundrums.. Mol Nutr Food Res 58(8):1589 PMID: 25088827
- 2. Halder M et al.. 2019. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease.. Int J Mol Sci 20(4) PMID: 30791399
- 3. Shearer MJ. 1995. Vitamin K.. Lancet 345(8944):229-34 PMID: 7823718
- 4. Tarento TDC et al.. 2019. A potential biotechnological process for the sustainable production of vitamin K(1).. Crit Rev Biotechnol 39(1):1-19 PMID: 29793354
- 5. Berkner KL. 2008. Vitamin K-dependent carboxylation.. Vitam Horm 78:131-56 PMID: 18374193
- 6. Kruk J et al.. 2026. Vitamin K in photosynthetic organisms.. Planta 264(3) PMID: 42570116
- 7. Huysman MW et al.. 1994. The vitamin K controversy.. Curr Opin Pediatr 6(2):129-34 PMID: 8032391
- 8. Stafford DW. 2005. The vitamin K cycle.. J Thromb Haemost 3(8):1873-8 PMID: 16102054
